A collaboration between Yale University and Google DeepMind has led to a rare scientific milestone: an artificial intelligence system that not only analyzed biological data but also generated and experimentally validated a new hypothesis for cancer treatment. Announced on October 15, 2025, the 27‑billion‑parameter foundation model, called Cell2Sentence‑Scale 27B, was developed to interpret single‑cell RNA […]
Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]
The phase 2 Co-PSMA trial conducted at St Vincent’s Hospital in Sydney evaluated 64Cu-SAR-bisPSMA, a novel copper-based PET imaging agent, against the standard 68Ga-PSMA-11 tracer in patients with biochemical recurrence of prostate cancer and low PSA levels. Results showed 64Cu-SAR-bisPSMA detected a statistically greater number of PSMA-positive lesions per patient than the standard agent, particularly […]
This Phase II study explores a novel approach to treating metastatic hormone-sensitive prostate cancer (mHSPC) through PSA-triggered intermittent therapy. Traditionally, men with mHSPC are managed with continuous androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors (ARPIs). This strategy has significantly extended survival but often leads to enduring side effects such as fatigue, […]
A new study published in Nature Signal Transduction and Targeted Therapy reports a major leap in the design of targeted cancer therapies through the development of an in vivo self-assembled nano-PROTAC (proteolysis targeting chimera) system capable of delivering dual-targeted degradation in castration-resistant prostate cancer (CRPC). PROTACs have reshaped the drug discovery landscape by inducing selective […]
Researchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]
A large international Phase 3 clinical trial is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]
A new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! First of all, thank you! The target has been reached. Thanks to your donations, I can renew our subscription to Kit.com and keep sending the newsletters! This week we have a great mix of clinical and preclinical research, including […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy